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Evidence  that  inﬂuenza  vaccination  during  pregnancy  is  safe  and  effective  at preventing  inﬂuenza  disease
in women  and  their  children  through  the  ﬁrst  months  of  life  is increasing.  Several  reports  of  reduced  risk
of adverse  outcomes  associated  with inﬂuenza  vaccination  have  generated  interest  in its  potential  for
improving  pregnancy  outcome.  Gavi,  the Vaccine  Alliance,  estimates  maternal  inﬂuenza  immunization
programs  in  low-income  countries  would  have  a relatively  modest  impact  on mortality  compared  to  other
new  or  under-utilized  vaccines,  however  the  impact  would  be  substantially  greater  if reported  vaccine
effects  on  improved  pregnancy  outcomes  were  accurate.  Here,  we  examine  the  available  evidence  and
methodological  issues  bearing  on  the relationship  between  inﬂuenza  vaccination  and  pregnancy  out-
come,  particularly  preterm  birth  and  fetal  growth  restriction,  and  summarize  research  needs.  Evidence
for  absence  of harm  associated  with  vaccination  at a point  in  time  is not  symmetric  with  evidence  of
beneﬁt,  given  the  scenario  in  which  vaccination  reduces  risk  of inﬂuenza  disease  and,  in turn,  risk  of
adverse  pregnancy  outcome.  The  empirical  evidence  for  vaccination  preventing  inﬂuenza  in  pregnant
women  is  strong,  but the  evidence  that  inﬂuenza  itself  causes  adverse  pregnancy  outcomes  is inconsis-
tent  and  limited  in  quality.  Studies  of  vaccination  and  pregnancy  outcome  have  produced  mixed  evidence
of  potential  beneﬁt  but are  limited  in terms  of  inﬂuenza  disease  assessment  and  control  of  confounding,
and  their  analytic  methods  often  fail  to fully  address  the longitudinal  nature  of  pregnancy  and  inﬂuenza
prevalence.  We recommend  making  full  use  of  results  of  randomized  trials,  re-analysis  of existing  obser-
vational  studies  to account  for  confounding  and  time-related  factors,  and  quantitative  assessment  of  the
potential beneﬁts  of  vaccination  in improving  pregnancy  outcome,  all of which  should  be  informed  by
the  collective  engagement  of experts  in inﬂuenza,  vaccines,  and  perinatal  health.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Background
The World Health Organization (WHO) has identiﬁed pregnant
omen and newborn children to be at high risk for seasonal
nﬂuenza disease morbidity and mortality [1]. Clinical trials have
hown that inﬂuenza vaccination during pregnancy can prevent
nﬂuenza disease in pregnant women and their newborn children
or the ﬁrst 6 months of life [2,3] with no indication of harm to the
ecipients or their offspring [2–4]. Moreover, some studies have
lso found improved birth outcomes (e.g., reductions in preterm
∗ Corresponding author. Tel.: +1 2063024843.
E-mail addresses: david savitz@brown.edu (D.A. Savitz), dfell@bornontario.ca
D.B. Fell), ortizj@who.int (J.R. Ortiz), nbhat@path.org (N. Bhat).
ttp://dx.doi.org/10.1016/j.vaccine.2015.08.041
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
birth) associated with vaccination [5,6], raising the possibility that
inﬂuenza vaccine programs may  have additional beneﬁts on new-
born health beyond prevention of postnatal inﬂuenza disease.
Given the potential impact of maternal inﬂuenza immunization
programs on maternal and child health worldwide, the WHO
Strategic Advisory Group of Experts on Immunization (SAGE) has
recommended pregnant women  be prioritized for inﬂuenza vac-
cine receipt in countries initiating or expanding their inﬂuenza
vaccine programs [1].
A major challenge to the adoption of maternal inﬂuenza immu-
nization in low-resource countries is the paucity of data regarding
the anticipated impact such programs would have on severe
illness. In 2013, Gavi, the Vaccine Alliance, modeled the antic-
ipated impact of maternal inﬂuenza immunization programs in
low-income countries [7] and concluded that the impact of such
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rograms on inﬂuenza disease mortality would be small compared
o the impact of other Gavi vaccine investments. However, if esti-
ates of vaccine effect on birth outcomes are accurate, the impact
f such programs in the poorest of countries would be substantially
reater than prior estimates and would likely inﬂuence investment
nd implementation decisions.
In 2013, SAGE noted that few countries had enacted maternal
nﬂuenza immunization policies [7]. It encouraged WHO  to quan-
ify the risk-beneﬁt ratio for maternal inﬂuenza immunization and
n response, WHO  created a taskforce of inﬂuenza experts, epidemi-
logists, disease modelers and health economists to synthesize
nd evaluate data on inﬂuenza disease incidence and risk rele-
ant to maternal inﬂuenza immunization [8]. Taskforce members
roduced a report commissioned by WHO  to assist in the interpre-
ation of the relevant literature, and this manuscript summarizes
he ﬁndings of this report. We  sought to provide a more complete
onceptual understanding of the research methods used to evaluate
aternal inﬂuenza immunization, assess the empirical evidence
earing on immunization policy, and suggest additional research
pproaches to address the uncertainties that remain.
. Objectives and methods
In this review of methodological and conceptual issues, we  con-
ider the evidence for a beneﬁcial effect of inﬂuenza vaccination
n pregnancy outcome, focusing primarily on preterm birth and
mall-for-gestational-age (SGA) birth, for which the research is
ost extensive. We  identiﬁed comparative studies of: (i) inﬂuenza
accination during pregnancy from two recently published reviews
5,9] and (ii) inﬂuenza disease during pregnancy from an ongoing
HO systematic evidence review [8]. We  summarized the ﬁndingsnderlying the empirical evidence for a beneﬁcial effect of inﬂuenza
accination on pregnancy outcome, considering methodology and
iologic plausibility that bear on a potential causal beneﬁt from
accination.
ig. 1. Hypothetical temporal alignment of ongoing pregnancies with inﬂuenza seasonali
re  typically administered (shown here as September to December). The dark gray line
epresents a typical inﬂuenza season, deﬁned as the ﬁrst and last occurrence of two cons3 (2015) 6430–6435 6431
3. Asymmetry between studies of potential harm and
potential beneﬁt of vaccination
The interpretation of inﬂuenza vaccine studies in pregnant
women has assumed that the same study design and analytic meth-
ods used to determine potential harm from immunization can be
directly applied to evaluation of potential beneﬁt (i.e., odds ratios
greater than 1.0 relating vaccination to adverse pregnancy outcome
would suggest harm; odds ratios less than 1.0 would therefore
reﬂect beneﬁt). While this seems intuitively reasonable, the under-
lying scenarios for harm and beneﬁt are not symmetric.
Under a scenario assuming potential harm, exposure to immu-
nization is viewed as a critical event at a speciﬁc point in gestation
that could cause an acute adverse event such as a birth defect,
miscarriage, or preterm birth, independent of the prevalence of
circulating inﬂuenza. In contrast, a reduced risk of adverse preg-
nancy outcome is presumed to be mediated by the effectiveness of
the vaccine in preventing inﬂuenza. Under this scenario, pregnant
women who  receive vaccine would be protected from infection,
which in turn would prevent disease and any adverse effects on
their pregnancy that would result from disease. The two compo-
nents required for beneﬁt are (1) reduction in risk of acquiring
inﬂuenza disease as a result of vaccination, and (2) an adverse
effect of inﬂuenza disease on the health of the pregnancy, reduced
through receipt of vaccine.
The beneﬁt of immunization derives from the sustained reduc-
tion in risk of acquiring disease during the inﬂuenza season,
typically a period of two  to three months every winter in tem-
perate climates; immunization status outside that window would
be irrelevant. Assuming the vaccine is only administered in the
pre-inﬂuenza season, the period of pregnancy at reduced risk for
inﬂuenza will depend on the calendar timing of the inﬂuenza sea-
son in relation to the pregnancy. For example, Fig. 1 illustrates that
a woman  who  conceives in early fall and is immunized during the
ﬁrst trimester (pregnancy B) would be at reduced risk of inﬂuenza
ty. The pre-inﬂuenza season represents the time period in which inﬂuenza vaccines
 represents the proportion of positive inﬂuenza specimens and the shaded area
ecutive weeks with ≥5% positive inﬂuenza specimens.
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uring most of the second trimester and early third trimester, both
f which coincide temporally with the hypothetical inﬂuenza sea-
on shown. However, she would receive no further beneﬁt in the
orm of a reduced risk of inﬂuenza disease after the end of the
nﬂuenza season. By extension, her developing fetus would also
nly stand to beneﬁt from potentially averted maternal inﬂuenza
isease during the same mid-pregnancy time period, since there
ould be no inﬂuenza disease to prevent during the latter part
f the gestation in this example. Thus knowing whether the preg-
ancy is vulnerable to maternal inﬂuenza disease at particular time
eriods during gestation is critical to assessing potential beneﬁts.
lthough there are case reports of adverse pregnancy outcomes,
uch as preterm birth, following early and late pregnancy inﬂuenza
isease [10], the recent WHO  evidence review on inﬂuenza disease
uring pregnancy found insufﬁcient data from comparative studies
o discern speciﬁc weeks, months, or trimesters in which inﬂuenza
ould produce increased risk [8].
As with all time-dependent states, pregnancies must be fol-
owed longitudinally, since a given woman is “unvaccinated” up
o the time of approximately two weeks after receipt of vaccine
when it is considered fully effective), and then “vaccinated” from
hat point forward [11,12]. Analytically, it is insufﬁcient to sim-
ly dichotomize a given pregnancy as vaccinated if vaccine was
eceived at some time during the pregnancy or unvaccinated oth-
rwise. Instead, there needs to be a week-by-week consideration
f the pregnancy with regard to vaccination status and circulating
nﬂuenza viruses, an approach that has been used by only a few
bservational studies to-date [13].
Finally, the two components required for beneﬁt must be
hained together and quantiﬁed to assess the potential effect of
accination on pregnancy outcome. The protection from inﬂuenza
s the ﬁrst component: the greater the baseline attack rate for
nvaccinated women and relative effectiveness of vaccination in
reventing disease, the greater the absolute beneﬁt from vaccina-
ion in preventing disease. The second component is the adverse
ffect of inﬂuenza disease on pregnancy outcome: the greater the
arm from inﬂuenza disease on pregnancy outcome, the greater the
eneﬁt in having avoided disease. Using a counterfactual frame-
ork for assessing the causal effect of vaccination on pregnancy
utcome, only those women who would have developed inﬂuenza
bsent vaccination but did not develop inﬂuenza with vaccina-
ion are the beneﬁciaries in averting inﬂuenza. Among those who
verted inﬂuenza through immunization, only those who  would
ave had a favorable outcome absent disease and an unfavor-
ble outcome with disease realize the beneﬁts to their pregnancy.
e lack sufﬁcient data to quantify the individual probabilities of
he events in this scenario. Nevertheless, from this illustration we
an see that not all pregnancies stand to beneﬁt from vaccina-
ion, due to the sizable proportions of women whose pregnancies
ill have little-to-no overlap with the inﬂuenza season, who will
ot develop inﬂuenza disease (regardless of vaccination), or who
evelop inﬂuenza disease but suffer no ill effects on pregnancy
utcome.
. Evidence for a beneﬁcial impact of vaccination on
regnancy outcome
.1. Effect of vaccination on risk of inﬂuenza
The assessment of whether vaccination covering the period of
regnancy yields beneﬁt starts with consideration of whether the
iven formulation of inﬂuenza vaccine is, in fact, effective in pro-
iding immunity against circulating inﬂuenza strains. Here, the
vidence indicates clearly that inﬂuenza vaccine is as effective for
regnant women as for other populations [14]. Two randomized3 (2015) 6430–6435
controlled trials of inﬂuenza immunization have demonstrated
a reduction in maternal inﬂuenza during pregnancy [2,3], one
of which estimated a 50% reduction in lab-conﬁrmed inﬂuenza
disease [3]. Thus, in years of moderate to high overall vaccine
effectiveness, immunized women  whose pregnancies pass through
the inﬂuenza season will incur only half of the disease that they
would have experienced absent vaccination. Observational studies
provide similar indication of beneﬁt [15,16], but indicate that the
magnitude of beneﬁt may  vary from season-to-season.
4.2. Inﬂuence of inﬂuenza on pregnancy outcome
A second critical piece of information needed to assess the
beneﬁt of vaccination is the magnitude of risk of adverse preg-
nancy outcome among women who  develop inﬂuenza. The recent
WHO  review assessing maternal inﬂuenza disease and adverse
birth outcomes found the evidence from comparative studies to
be inconsistent, in addition to being limited in both quantity
and methodological quality [8]. Some studies report little or no
increased risk of preterm birth among women who were hospital-
ized with inﬂuenza or other respiratory diseases during pregnancy
[17,18], whereas others ﬁnd a markedly elevated relative risk
(about four-fold) of preterm birth [19,20]. While the latter studies
may  reﬂect the most severe manifestations of inﬂuenza disease,
there are also concerns that the increased rates of hospitalizations
are due more to clinical practice than to disease severity and may
also be a nonspeciﬁc marker of concern with the health of the
pregnancy. Nonetheless, there is some replicated evidence, albeit
inconsistent, suggesting hospitalization with severe inﬂuenza dis-
ease during pregnancy may  be associated with preterm birth,
particularly for pandemic 2009 A (H1N1) disease [20,21].
Among studies that have used laboratory conﬁrmation among
women presenting with symptoms of inﬂuenza-like illness, there
was evidence of a small increased risk of preterm birth in some
studies [21,22], but not in others [23]. A concern in several of these
studies is that other maternal-fetal problems in pregnancy moti-
vated the testing, introducing a possible diagnostic bias [20,21].
Studies of self-reported respiratory illness during pregnancy (as
opposed to laboratory-conﬁrmed inﬂuenza) are less relevant given
that in most cases only a small proportion of non-speciﬁc respi-
ratory illnesses are in fact due to inﬂuenza virus infection [24,25].
Nevertheless, studies of conﬁrmed inﬂuenza in pregnant women
do not indicate that mild or subclinical inﬂuenza disease in moth-
ers is associated with worse birth outcome [13,23]. Fewer studies
have addressed SGA birth than preterm birth, but provide equally
inconsistent results: three studies reported no increased risk asso-
ciated with inﬂuenza disease during pregnancy [22,23,26] while
two others found an increased risk [18,23].
4.3. Evidence that vaccination prevents adverse pregnancy
outcomes
The observational epidemiologic studies that considered the
potential adverse effect of inﬂuenza vaccination during pregnancy
on infant health outcomes were recently summarized in system-
atic reviews of the evidence on preterm birth and fetal death [5,6].
Fell et al. identiﬁed 26 observational studies and one randomized
clinical trial that were pertinent and found sufﬁcient heterogeneity
among the studies to preclude generating a meaningful summary
estimate [5]. Among the 19 studies of preterm birth, 15 yielded
adjusted odds ratios in the range of 0.6–1.0, and one suggested a
markedly increased risk. While a pooled estimate was not gener-
ated, it would appear that such an estimate would fall in the range of
0.7–0.9, implying a reduced risk associated with inﬂuenza vaccina-
tion. The authors reasonably interpreted their results as providing
rather strong evidence against an adverse effect of inﬂuenza vaccine
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eceipt but interpreted the evidence of beneﬁt cautiously. Given lack
f evidence of harm associated with vaccination [4–6,27], the con-
ern with adverse fetal effects related to inﬂuenza vaccine received
n pregnancy has largely abated.
Two studies have compared pregnancy outcomes occurring
mong immunized and non-immunized women  within time
eriods deﬁned by inﬂuenza virus circulation [28,29]. If vaccina-
ion truly prevents adverse outcomes by preventing inﬂuenza, then
he beneﬁt will be most apparent when there is a high baseline
isk of inﬂuenza disease. For births during periods of intensive
nﬂuenza virus activity in Georgia between 2004 and 2006, Omer
t al. reported an odds ratio for preterm birth of 0.28 (0.11–0.74)
nd an odds ratio for SGA birth of 0.31 (0.13–0.75), more pro-
ounced than for births during periods without circulating virus
28]. Steinhoff et al. examined the data from a randomized trial
onducted in Bangladesh reported by Zaman et al. and assessed
he association between inﬂuenza vaccination and preterm birth
tratiﬁed into time periods deﬁned as having limited or proven
irus circulation [2,29]. When inﬂuenza was actively circulating,
he adjusted odds ratio for preterm birth was 0.32 (0.05–2.29) and
or SGA birth it was 0.44 (0.19–0.99), a more pronounced appar-
nt beneﬁt than in periods in which there was no inﬂuenza virus
irculating [29].
Rather than deﬁning the time period by when the birth occurred,
he focus should be on the period of gestation during which there
as risk of inﬂuenza virus exposure. The beneﬁt is not conferred
t the time of vaccination; rather, the reduced risk would be
xperienced over this critical period of gestation, which would be
ssociated, but not fully aligned, with the timing of birth. In addi-
ion, when estimating the full impact of the intervention, the effect
easure found in the fraction of the population experiencing the
ighest risk of disease should not be applied to the population as a
hole.
A subtle problem, but one that may  be relevant to preterm birth
t least, concerns the potential for cohort truncation bias. If vac-
ines are administered in the pre-inﬂuenza season (for example,
eptember to October), and the focus is on births that occur in the
nﬂuenza season (November to February), then a study that selects
ased on timing of birth rather than timing of conception is vul-
erable to selection of long or short gestations [30]. Depending on
he exact timing, deﬁning populations by “date of delivery” rather
han by “date of conception” can distort results for preterm birth.
Whereas preterm birth could, in theory, be precipitated by an
cute event, such as the development of inﬂuenza disease, the like-
ihood of vaccination having a pronounced effect on fetal growth
s less plausible given that fetal growth is an ongoing physiologic
rocess occurring over an extended period, particularly in the third
rimester. Unless inﬂuenza illness were to cause signiﬁcant chronic
lacental damage that could affect fetal growth, an effect that has
ot been documented, it seems implausible that this ongoing pro-
ess could be disrupted so markedly by an acute event as to affect
his outcome to the extent that has been reported [28,29].
Finally, there is the reported magnitude of effects, with some
tudies suggesting that upwards of two-thirds of all preterm births
nd more than half of SGA births were avoided for deliveries
ccurring in the inﬂuenza season [28,29]. To provide some context,
t is important to note that there are no other known exogenous
nﬂuences on preterm birth that come even close to this magnitude
f effect (i.e., a three-fold reduction in risk) [31,32]. In scrutinizing
he results for potential artifacts, it is useful to consider the types
f predictors (not even necessarily causes)  that are associated
ith marked differences in preterm birth. There are proximal
redictors in the course of pregnancy that are strongly predictive
f preterm birth, in part because some of these factors lead to
edically indicated delivery prior to completing 37 weeks of
estation. A proﬁle that includes a prior preterm birth, pregnancy3 (2015) 6430–6435 6433
complications, presence of underlying chronic disease, and an
array of unfavorable lifestyle factors, is associated with a markedly
elevated risk of preterm birth (and fetal growth restriction). It is
plausible but unknown whether vaccine receipt varies in relation
to these markers of risk for adverse pregnancy outcome.
Several studies suggest that inﬂuenza vaccination may not,
in fact, prevent preterm birth. Three studies examined the risk
of preterm birth according to the period of pregnancy in which
the vaccine was  administered and found no reduction for those
vaccinated in the ﬁrst or second trimester, despite the fact that
such vaccination when administered early would protect against
inﬂuenza for the greatest proportion of pregnancy [33–35]. In fact,
a reported reduction in risk limited to late-pregnancy vaccination
may  be more consistent with the hypothesis of “selective vacci-
nation”, since the proximal predictors of adverse outcome are not
identiﬁed until later in the course of pregnancy, or with “immor-
tal time bias”, since the pregnancy had to “survive” until the time
of vaccination [12]. A number of methodologically strong obser-
vational studies did not report any evidence of decreased risk of
preterm birth among vaccinated mothers [13,33–35]. As reﬂected
by the evidence of heterogeneity in the systematic evidence review
[5], it seems unlikely that these reﬂect random error only, but
there are so many methodologic subtleties in cohort deﬁnitions
and analytic methods that the critical features driving the results
are difﬁcult to discern.
5. Confounding by correlates of vaccine receipt
The results of the observational studies indicating improved
pregnancy outcome may  well be attributable to confounding rather
than a causal impact of vaccination. Women  with the most favor-
able risk proﬁle may  be more likely to receive the vaccine, a
phenomenon that was  found to exaggerate the apparent beneﬁt of
vaccination in preventing death among elderly inﬂuenza vaccine
recipients [36,37]. In observational studies, it would be expected
that the women  receiving vaccine would be more highly educated,
less likely to use tobacco, have a more optimal pre-pregnancy
weight and diet during pregnancy, and be more likely to adhere to
prenatal care guidelines. Indeed, a number of observational studies
of inﬂuenza immunization during pregnancy have shown impor-
tant baseline differences between vaccinated and non-vaccinated
women along these lines [13,33,34,38].
Many of the observational studies of inﬂuenza vaccination and
pregnancy outcome have, in fact, measured and made statistical
adjustments for confounding factors, and such adjustments have
tended to reduce the magnitude of reduced risk for vaccinated
women [5]. However, even with careful attention to measuring and
adjusting for correlated predictors of favorable pregnancy outcome,
the ability to fully account for this phenomenon using statistical
methods is limited. To the extent that our operational measures
of “healthful lifestyle” do not fully capture the construct—and it
is inevitable that they do not—there will be residual confound-
ing, even with an attempt to remove the bias. A small reduction
in the relative risk of adverse pregnancy outcome associated with
vaccination may  well be a product of residual confounding.
6. Conclusions and research recommendations
In 2013, SAGE recommended that WHO  quantify the bene-
ﬁts of maternal inﬂuenza immunization in order to strengthen
investment and implementation decisions [39]. The evidence for
maternal immunization to prevent inﬂuenza disease in mothers
and infants is strong, but the potential beneﬁts of inﬂuenza vaccine
exposure on pregnancy outcome are uncertain. Clear evidence of
this additional beneﬁt from inﬂuenza vaccination would strongly
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nﬂuence maternal inﬂuenza immunization program investment
ecisions and vaccine use globally.
Despite a number of studies suggesting that inﬂuenza vacci-
ation is associated with a reduced risk of adverse pregnancy
utcomes, these observational studies possess important metho-
ologic limitations. To the extent that receipt of vaccine is a
iscretionary activity on the part of pregnant women  and their
linicians, baseline differences among vaccine recipients and non-
ecipients may  only be avoidable through randomized trials.
owever, in the well-known example of hormone replacement
herapy and risk of cardiovascular disease, the discrepant ﬁnd-
ngs from randomized and observational studies resulted largely
rom the design and analytic approach of the observational studies
ather than from a lack of randomization [40]. Similarly, many of
he observational studies examining maternal inﬂuenza immuniza-
ion fail to address the inherently longitudinal and time-varying
ature of the phenomenon of interest, instead treating receipt
f vaccine as a ﬁxed attribute. Besides having the advantage of
andomization, intervention trials generate analyses that follow
omen through time to determine their pregnancy outcome, thus
xplicitly accounting for the timing of vaccine administration in
elation to inﬂuenza circulation and gestational age. To the extent
hat observational studies can do the same, and adjust rigorously
or potential confounding through regression or propensity score
nalysis, they should be able to approximate the results of random-
zed trials. Several recently completed clinical trials will provide
ital new insights on the question of inﬂuenza vaccine and preg-
ancy outcome [41], but observational studies will still be required
o broaden the range of populations studied and the timing of vac-
ine administration. Together, randomized trials and well-designed
bservational studies can produce complementary evidence, pro-
iding policy-makers with the data necessary to assess full beneﬁt.
In addition, it is important to note that all the randomized tri-
ls have been conducted in resource-constrained settings, whereas
early all observational studies have occurred in North America and
urope. While it is theoretically possible to conduct randomized
rials in Western countries and observational studies in resource-
onstrained settings, there are substantial logistical and ethical
arriers to either approach. To the extent that we can integrate
ndings across the ongoing and completed trials, the inferences
ill come more quickly.
Given our continued reliance upon observational studies to
ssess the potential impact of maternal inﬂuenza immunization
n pregnancy outcomes, our ﬁrst recommendation is to re-analyze
elected observational studies using the methods described above.
his would only be possible for studies with extensive information
n covariates that may  act as confounders and longitudinal infor-
ation on the timing of pregnancy, inﬂuenza activity in the area,
nd receipt of vaccine. Some studies clearly approximate this ideal
13,33], and generally show no beneﬁt of vaccination in reducing
reterm birth, although it is important to note that even when using
hese robust analytic approaches, Pasternak et al. found a lower risk
f fetal death among women vaccinated with 2009 monovalent
andemic inﬂuenza A (H1N1) vaccine (adjusted hazard ratio: 0.44,
5% CI: 0.20–0.94) [42], while Haberg et al. did not (adjusted hazard
atio: 0.88, 0.66–1.17) [13]. These ﬁndings require further investi-
ation given the paucity of studies on inﬂuenza disease, inﬂuenza
accination, and fetal death [5,8].
A second recommendation is for a careful, quantitative assess-
ent of the potential impact of vaccine on pregnancy outcome
t the population level that would consider the baseline risk of
nﬂuenza throughout the year, the timing of vaccination in rela-
ion to gestation, the impact of vaccination on the risk of inﬂuenza
isease, and the impact of inﬂuenza disease on the outcome of preg-
ancy. As discussed, the only women who stand to beneﬁt from
eceipt of vaccine are those whose pregnancies coincide with the3 (2015) 6430–6435
part of the year when there is a risk of developing inﬂuenza, and the
only ones who  actually beneﬁt are those in whom disease is pre-
vented, resulting in a favorable outcome that would otherwise have
been unfavorable. Perhaps studies in settings in which inﬂuenza
occurs throughout the year would help to quantify the potential
beneﬁt. As noted above, it seems unlikely that vaccination could
prevent upwards of 50% of all preterm births or instances of fetal
growth restriction during the inﬂuenza season [28,29], but a more
systematic analysis of these scenarios would inform research and
policy.
A ﬁnal recommendation is that we must engage both inﬂuenza
experts and perinatal researchers to design and evaluate studies on
this topic collaboratively. Much of the work to date has been done
by experts in either one area or the other, and the ensuing limita-
tions of this segregated approach are apparent in both directions.
Only through the combined efforts of these disciplines can impor-
tant and subtle features of both inﬂuenza and perinatal health be
integrated into the design of future studies.
Studies evaluating the potential beneﬁt of maternal inﬂuenza
immunization on pregnancy outcomes will continue to be con-
ducted, most of which will be observational. Data from these
studies could prove instrumental for countries weighing the poten-
tial beneﬁts of implementing maternal inﬂuenza immunization
programs, particularly those with limited budgets and multiple
competing priorities. Therefore, researchers, policy-makers, and
funding agencies must ensure that such data are reliable, a goal that
can only be achieved through attention to fundamental aspects of
study design and interpretation.
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